Press Releases

HAVN Life Natural Health Products Now Available on Amazon.com

The Company continues to grow its global retail footprint by partnering with the world’s largest ecommerce site Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company developing natural health products and innovative therapies to support brain health and cognitive function, is pleased to …

HAVN Life Natural Health Products Now Available on Amazon.com Read More »

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research …

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research Read More »

HAVN Life Announces Termination of Amalgamation Agreement to Acquire Spore Life Sciences

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company developing natural health products and innovative therapies to support brain health and cognitive function, announces that the amalgamation agreement entered into with Spore Life Sciences Inc. (“Spore”), as announced on December 20, 2021, has …

HAVN Life Announces Termination of Amalgamation Agreement to Acquire Spore Life Sciences Read More »

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market

The Agreement allows HAVN Life to export naturally derived psilocybin from its Jamaica facility and grows roster of supply partners in the U.S. market Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as …

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market Read More »

HAVN Life Session at Psychedelic Capital: Jan 2022 by Microdose

Tim Moore and Michael Zavet to speak on Thursday, January 27 at 4:25pm EST Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and enhance the capabilities of …

HAVN Life Session at Psychedelic Capital: Jan 2022 by Microdose Read More »

HAVN Life Announces Gary Leong’s Appointment to Board of Directors

Mr. Leong brings with him a wealth of scientific and regulatory experience Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind, is pleased to announce …

HAVN Life Announces Gary Leong’s Appointment to Board of Directors Read More »

HAVN Life Enters into Definitive Agreement to Acquire Spore Life Sciences Inc.

The Subscription-based Functional Mushroom Company has established a significant consumer base in the U.S. Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company developing natural health products and innovative therapies to support central nervous system health and enhance the capabilities of the mind, …

HAVN Life Enters into Definitive Agreement to Acquire Spore Life Sciences Inc. Read More »

HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S. for Research Purposes

The Company was able to export naturally derived psilocybin to their California-based Supply Partner, Mycrodose Therapeutics late last week. Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential active pharmaceutical ingredients (APIs) …

HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S. for Research Purposes Read More »

HAVN Life To Present at upcoming SNN Network Canada Virtual Event

CEO Tim Moore to present and host a Q & A for investors on December 8 at 2:30pm EST Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health …

HAVN Life To Present at upcoming SNN Network Canada Virtual Event Read More »

HAVN Life Successfully Exports Psilocybin from its Jamaica Facility into Canada

The Company Signs Supply Agreement with Nectar Health Sciences Laboratory Division Inc. to provide naturally derived psilocybin for research and development of therapeutic products Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of …

HAVN Life Successfully Exports Psilocybin from its Jamaica Facility into Canada Read More »

Scroll to Top